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Abstract: Aberrant angiogenesis is essential for the
progression of solid tumors and hematological malig-
nancies. Antiangiogenic therapy is one of the most
promising approaches to treat such diseases. Dobesi-
late is an oral agent for treatment of vascular compli-
cations of diabetic retinopathy. We have examined the
possibility that this compound could interfere with the
process of angiogenesis in a mouse gelatine sponge as-
say using acidic fibroblast growth factor (aFGF) as an
inducer of neovascularization. According to the results
reported here, dobesilate remarkably reduced vessel
ingrowth in aFGF-containing subcutaneous sponges
in mice. These findings suggest that dobesilate could
be an effective agent in the treatment of angiogenesis-
dependent diseases involving FGFs.
Key words: Dobesilate, Fibroblast growth factor, An-
giogenesis, Mouse gelatine sponge assay.
INTRODUCTION
Angiogenesis is a sequence of events that is essential
for a broad array of physiological events, including
embryogenesis, menstrual cycle and wound healing.
Angiogenesis is also involved in pathological situations
such as tumor growth, atherosclerosis, diabetic
retinopathy, chronic inflammation, and endometriosis
[1, 2]. The use of angiostatic agents seems a new thera-
peutic option for some of these pathological processes
[3, 4]. Under both physiological and disease-associated
conditions, angiogenesis is a complex multistep pro-
cess involving an orchestrated interaction of endothe-
lial cells and pericytes with both the extracellular ma-
trix and soluble angiogenic factors. Angiogenesis is
controlled by a counteracting balance between antian-
giogenic and proangiogenic factors [3], which suggests
that inhibition of even a single major angiogenic pro-
moter may cause inhibition of the process. Fibroblast
growth factor (FGF) and vascular endothelial growth
factor (VEGF) are major proangiogenic promoters [5,
6]. The FGFs are a group of 23 closely related pep-
tides [7] with a paramount of biological functions on a
variety of cell types. It has been repeatedly shown that
the two FGF prototypes, acidic FGF (aFGF, FGF-1)
and basic FGF (bFGF, FGF-2), are potent angiogenic
factors in vivo [5]. 
During the multiple stages of tumor development,
FGFs exert highly pleiotropic functions. They some-
times promote tumor cell proliferation in an autocrine
fashion; they can stimulate cell survival, and they very
often participate in the induction of tumor angiogene-
sis [8, 9]. FGFs interact with certain specific tyrosine-
kinase receptors (FGFRs) [10] and heparan sulfate
proteoglycans (HSPGs) of the cell surface [11]. As-
semblage of an HSPG/FGF/FGFR ternary complex
triggers mitogenesis, an initial step of angiogenesis
[12]. To date, much effort has been directed toward
the discovery of antiangiogenic agents and the evalua-
tion of their therapeutic applications [1]. Calcium
dobesilate is a drug commonly used in the treatment
of diabetic retinopathy and chronic venous insufficien-
cy [13]. Although the mechanism of action of dobesi-
late is as yet unclear, the pharmacology of dobesilate
reveals its ability to decrease capillary permeability, as
well as platelet aggregation and blood viscosity [14].
Recent experimental data suggest that antiangiogenesis
can be involved in the therapeutic benefit of calcium
dobesilate in diabetic retinopathy [15, 16]. Further-
more, topical dobesilate treatment showed efficacy to
clear basal cell carcinoma (BCC) [17], an epidermal an-
giogenesis-dependent disease characterized by an
overexpression of FGF [18].The above findings led us
to test calcium dobesilate for its effects on vascular
proliferation using a subcutaneous sponge assay for
angiogenesis [19].
MATERIAL AND METHODS
Chemicals: Calcium dobesilate (Doxium®; calcium 2,5-
dihydroxybenzene sulfonate) was provided by Labora-
torios Dr. Esteve (Barcelona, Spain). Its chemical
structure is shown in Fig. 1. aFGF used in this study
was synthesized and purified as described [20]. 
Animals: Pathogen-free C57/BL/6 mice (Charles River)
weighing 30 ± 6g were used. The animals were housed
in plastic cages under temperature- and humidity-con-
trolled conditions; food and water were available ad li-
bitum, and a 12-h light/dark schedule was maintained.
The animal welfare guidelines of the National Institute
of Health and the European Union were followed.
Angiogenesis assay: Sterile gelatine sponge cubes of
1mm3 (Curaspon Dental, Clinimed Holding, Zwanen-
burg, The Netherlands) were implanted subcutaneous-
ly in the backs of the mice after induction of intraperi-
toneal anesthesia as described [21]. The animals were
divided into four groups. In group A (n = 10) the im-
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planted sponges were embedded with 200µl of phos-
phate-buffered saline (PBS) containing 29µg/ml he-
parin. In group B (n = 12), the solution embedding
the sponges contained, in addition, 10µg/ml aFGF. In
group C (n = 12), the sponges were embedded with
the same solution as that in Group B plus 50µM calci-
um dobesilate. The concentration of dobesilate used in
these studies is the same which elicits the highest in-
hibitory effect of the proliferation of glioma cell cul-
tures [22]. After implantation of the sponges into the
subcutaneous pouch, the skin was sutured. All proce-
dures were performed under sterile conditions. For an-
giogenesis evaluation, the mice were re-anesthetized as
described 7 days after the implants, and the sponges
were surgically extracted and fixed in situ. Neovascu-
larization was assessed in deparaffined microtome sec-
tions stained with hematoxylin and eosin and quanti-
fied with computerized morphometric software con-
nected to a microscope. Ingrowth of neovessels into
sponges was assessed by measuring the surface area
with erythrocyte content. Neovascularization was ana-
lyzed in four predetermined visual fields in three dif-
ferent sections at 10-fold magnification. 
Statistical analysis: Results were expressed as mean ±
standard error of the mean (S.E.M.) of n determina-
tion. A Student’s t-test for unpaired samples was used
for statistical analysis. Significant differences were ac-
cepted for p<0.05.
RESULTS
An evaluation of the in vivo relevance of dobesilate as
an angiogenesis inhibitor was carried out using a stan-
dard mouse angiogenesis assay [19]. Figure 2 illustrates
the inhibitory effect of dobesilate on neovasculariza-
tion induced by aFGF in gelatine sponges subcuta-
neously implanted in mice. No new capillaries were
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Fig. 2. In vivo antiangiogenic effect of dobesilate in the mouse gelatine sponge assay. Representative hematoxylin and eosin his-
tological sections, at day 7, of sponge implants embedded in PBS (a), in PBS plus aFGF (b) and in PBS plus aFGF and dobesi-
late (c). Note the absence of neovessels in sponges embedded with PBS (a) and the decreased angiogenesis in sponges contain-
ing dobesilate (c) in comparison to sponges embedded with aFGF alone (b). The arrows in c indicate vessels plugged with ery-
throcytes. The exuberant cell infiltration depicted in (b) decreased significantly in sponge implants embedded with aFGF and
dobesilate. Original magnification x 50. Quantification of the angiogenesis was performed by calculating the area covered by
erythrocytes (d).
Fig. 1. Chemical struc-
ture of calcium dobesi-
late.
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found in sponges loaded with PBS alone (Fig 2a),
whereas sponges containing aFGF were infiltrated by
many new blood vessels and inflammatory cells (Fig
2b). In sponges embedded with aFGF plus dobesilate,
neovessels were scattered and slightly more inflamma-
tory cells were present (Fig. 2c). Equivalent results
were obtained when aFGF was substituted by bFGF
and also when calcium dobesilate was substituted by
magnesium or potassium dobesilate (not shown). A
quantitative analysis, based on a computation of the
areas containing erythrocytes in animals of groups B
and C, respectively (Fig. 2d), shows that dobesilate de-
creases angiogenesis by 85.28% [p<0.0001; unpaired
Student’ t-test]. The angiostatic agent dobesilate did
not appear to affect the overall health of the mice, as
the body weights of the mice in the various treatment
groups were not significantly different. The behavior
of the mice during treatment was also normal.
DISCUSSION
New blood vessel formation (angiogenesis) is a funda-
mental event in the process of tumor growth and
metastatic dissemination. FGF, which has the potential
to induce other angiogenic factors including VEGF
[for review see, ref. 23] and hepatocyte growth factor
(HGF) [24-26] that also play an important role in tu-
morigenesis [27], is likely to be a main member of the
“angiogenic orchestra” [23]. Furthermore, since FGF
exhibits a synergistic effect with VEGF it is conceiv-
able that both FGF and VEGF are required for the
switch to the angiogenic phenotype during tumorigen-
esis [28, 29]. Thus, therapeutic approaches that are
based on the inhibition of FGF function may allow, in-
directly, the simultaneous targeting of different angio-
genesis factors. Moreover, such treatment may boost
the therapeutic inhibition of other growth factors in
cases in which these growth factors are expressed and
act in a synergistic manner. This well-established role
of FGF in promoting tumor angiogenesis, and in the
pathogenesis of human cancers, has led to the rational
design and development of low molecular mass agents
that selectively inhibit FGF activity. A recent list of
compounds showing such inhibitory activity includes
some naphthalenesulfonate derivatives [21, 30], a short
peptide domain of platelet factor 4 (PF-447-70) [31] and
semisynthetic heparins [32]. The aim of the study re-
ported here was to evaluate in a mouse sponge model
of angiogenesis whether dobesilate could be included
in that list of low molecular mass inhibitors of FGFs.
Our data demonstrate that dobesilate effectively inter-
feres with FGF-induced angiogenesis, in agreement
with previous reports which could suggest an antian-
giogenic effect of this compound [15, 16]. Further-
more, a previous report also shows a proapoptotic ac-
tivity of dobesilate towards glioma cells, whose viabili-
ty autocrinely depends on FGF [22]. Recently it has
been reported that dobesilate inhibits rat choroidal an-
giogenesis in vitro through, at least in part, inhibition
of VEGF via antioxidant properties of dobesilate [16].
Our study suggests that the antiangiogenic effects of
dobesilate could be mediated, at least in part, by the
inhibition of FGF. One of the most serious clinical
side effects associated with the prolonged use of an-
tiangiogenic therapy is the frequency of thrombotic
events observed in several clinical trials [27, 33]. In
this context, dobesilate, by its antithrombotic activity
could be a safe and advantageous angiostatic agent.
Since, as demonstrated in this study, dobesilate in-
terferes with the process of angiogenesis, this com-
pound seems a very promising lead for further devel-
opments in the treatment of cancer and other angio-
genesis-dependent diseases. Work is in progress to an-
alyze the structural relationship between dobesilate
and FGF and FGFR.
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